Cost of migraine management: A pharmacoeconomic overview

American Journal of Managed Care

Volumn 4, Issue 4, 1998, Pages 531-545

  Rapoport, Alan M ^a,b   Adelman, James U ^c,d  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Adelman Headache Center   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ATENOLOL; BUTALBITAL; BUTORPHANOL TARTRATE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; FLUOXETINE; IBUPROFEN; METHYSERGIDE MALEATE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROMETHAZINE; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN SUCCINATE; TRICYCLIC ANTIDEPRESSANT AGENT; TYLOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL; WIGRAINE; ZOLMITRIPTAN;

COST CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; MENTAL STRESS; MIGRAINE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ANALGESICS; CHRONIC DISEASE; COST OF ILLNESS; DISEASE MANAGEMENT; DRUG COSTS; HUMANS; MIGRAINE DISORDERS; PATIENT EDUCATION; PREVENTIVE MEDICINE; RELAXATION TECHNIQUES; STRESS, PSYCHOLOGICAL; UNITED STATES;

EID: 0031904033     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders and suicide attempts: An epidemiologic study of young adults. Psychiatry Res 1991;37:11-23.
2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: A prevalence study. J Clin Epidemiol 1991;44:1147-1157.
3. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-69.
4. Henry P, Michel P, Brochet B. A nationwide survey of migraine in France: Prevalence and clinical features in adults. Cephalalgia 1992;12:229-237.
5. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992;152:1273-1278.
6. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: A Canadian population survey. Can J Neurol Sci 1993;20:131-137.
7. Stang PE, Osterhaus JT. Impact of migraine in the United States: Data from the National Health Interview Survey. Headache 1993;33:29-35.
8. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. PharmacoEconomics 1992;2:67-76.
9. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994;28:659-664.
10. To T, Wu K. Health care utilization and disability of migraine: The Ontario Health Survey. Can J Public Health 1995;86:195-199.
11. Stang PE, Yanagihara T, Swanson JW, et al. A population-based study of migraine headaches in Olmsted County, Minnesota. Neuroepidemiology 1991;10:297-307.
12. Stang PE, Osterhaus JT, Celentano DD. Migraine: Patterns of healthcare use. Neurology 1994;44(suppl 4):S47-S55.
13. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: A national probability sample study. Headache 1992;32:223-228.
14. Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992;327:1109-1114.
15. Gutkin AJ, Holburn SW, Walker JR, Anderson BA. Treatment integrity of relaxation training for tension headaches. J Behav Ther Exp Psychiatry 1992;23:191-198.
16. Gutkin AJ, Holborn SW, Walker JR, Anderson BA. Cost-effectiveness of home relaxation training for tension headaches. J Behav Ther Exp Psychiatry 1994;25:69-74.
17. Silberstein SD. Preventive treatment of migraine: An overview. Cephalalgia 1997;17:67-72.
18. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc 1996;71:1055-1066.
19. Adelman JU, Von Seggern R. Cost considerations in headache treatment. Part 1: Prophylactic migraine treatment. Headache 1995;35:479-487.
20. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969;21:263-268.
21. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia 1997;17:81-83.
22. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 197;49:1210-1218.
23. Imitrex® (sumatriptan) product information. Glaxo Wellcome Inc., Research Triangle Park, NC, 1997.
24. Sheftell FD, Weeks RE, Rapoport AM, et al. Subcutaneous sumatriptan in a clinical setting: The first 100 consecutive patients. Headache 1994;47:46-51.
25. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Man Care 1996;2:1407-1416.
26. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996;36:538-541.
27. Cohen JA, Beall DG, Beck A, et al. Use of sumatriptan to treat migraines in patients in a group model HMO: Health care use, health-related quality of life, and clinical effectiveness. Neurology 1996;46:A323. Abstract.
28. Jhingran P, Cady RK, Rubino J. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996;42:36-42.
29. Ferrari MD. 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Neurology 1997;48(suppl 3):S21-S24.
30. 1B/1D agonist: An overview of efficacy. Cephalalgia 1997;17(suppl 18):28-40.
31. Solomon GD. Evolution of the measurement of quality of life in migraine. Neurology 1997;48(suppl 3):S10-S15.
32. Klassen A, Webster C, Laurenza A, et al. Naratriptan tablets are effective and well-tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, parallel-group trial. Neurology 1997;48:A66. Abstract.
33. Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, crossover study. Neurology 1997;49:1485-1490.
34. Dahlof C. The ideal 5-HT1D agonist. In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. Philadelphia: Lippincott-Raven; 1997:243-251.
35. Block GA, Smith M, Jiang K, et al. Rizatriptan (MK-0462) for the acute treatment of migraine and migraine recurrence. Neurology 1997;48:A68. Abstract.
36. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch Neurol 1996;53:1132-1137.
37. Markley HG. Chronic headache: Appropriate use of opiate analgesics. Neurology 1994;44(suppl 3):S18-S24.
38. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press; 1990:485-521.
39. Kudrow L, Kudrow DB, Sandweiss JH. Rapid and sustained relief of migraine attacks with intranasal lidocaine: Preliminary findings. Headache 1995;35:79-82.
40. Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine: Randomized, double-blind, controlled trial. JAMA 1996;276:319-321.